UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~WASHINGTON~~Washington, D.C. 20549

FORM 6-K

~~REPORT~~Report OFof ~~FOREIGN~~Foreign ~~PRIVATE~~Private ~~ISSUER~~Issuer

~~PURSUANT~~Pursuant TOto ~~RULE~~Rule 13a-16 ORor 15d-16 ~~UNDER~~

~~THE~~Under ~~SECURITIES~~the ~~EXCHANGE~~Securities ~~ACT~~Exchange OFAct of 1934

For the month of ~~October~~January ~~2025~~2026

Commission File Number: 001-41115

GENENTA SCIENCE S.P.A.

(Translation of ~~registrant~~Registrant’s ~~name~~Name into English)

Via Olgettina No. 58

20132 Milan, Italy

(Address of ~~Principal~~principal ~~Executive~~executive ~~Offices~~office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K, including Exhibit 10.1 and 10.2, is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).

Other Events

OnProposed ~~October~~Change ~~29,~~to ~~2025,~~Corporate ~~Genenta~~Name ~~Science S.p.A. (the “Company”) held its Ordinary~~ and ~~Extraordinary~~Nasdaq ~~Shareholders’~~Ticker ~~Meeting in virtual meeting format. At the Ordinary and Extraordinary Shareholders’ Meeting, the Company’s shareholders approved the following resolutions:~~Symbol

●As previously disclosed in the Current Report on Form 6-K of Genenta Science S.p.A. (the “Company”) filed with the U.S. Securities and Exchange Commission on November 3, 2025, at the Company’s Ordinary and Extraordinary Shareholders’ Meeting held on October 29, 2025, the Company’s shareholders approved the proposed amendment to Article 4 of the Company’s by-laws to extend the Company’s corporate purpose to include all sectors covered by the Italian Law Decree 21/2012 (i.e. Golden Power legislation);. In connection with the extension of the Company’s corporate purpose, the Company intends to adopt the new corporate name of “Saentra Forge S.p.A.” and a new Nasdaq ticker symbol of “SAEN.” The new corporate name and the new Nasdaq ticker symbol will become effective subject to approval of the name change by the Company’s shareholders at an Extraordinary Shareholders’ Meeting that will be held on March 25, 2026, at 5:00 p.m., on first call, and, if necessary, on March 26, 2026, at 5:00 p.m., on second call.

~~● the increase in the number of members of the Board of Directors from three (3) to five (5) members;~~A.T.C. Acquisition

●In ~~the~~addition ~~appointment~~to ofits ~~two~~current focus ~~new~~as ~~directors~~a toclinical-stage ~~the~~biotechnology ~~Company’s~~company ~~Board~~focused on the development of ~~Directors~~Temferon, ~~Miguel~~the ~~Maria~~Company ~~Mutti~~intends ~~and~~to ~~Giacomoantonio~~expand ~~Paracchi~~as a biotech, ~~effective~~defense, aerospace asand ofnational ~~October~~security ~~29,~~industrial ~~2025,~~consolidator tofocused ~~serve~~on ~~until~~acquiring ~~the~~majority ~~Company’s~~ownership ~~Shareholders’~~of ~~Meeting~~privately ~~approving~~held ~~the~~Italian ~~financial~~businesses operating ~~statements~~in asnational-security ofregulated ~~December~~sectors ~~31,~~contemplated ~~2025~~by the Italian Golden Power legislation.

~~Armon~~In connection with this strategic R.expansion, ~~Sharei~~on January 24, Ph2026, the Company entered into an Investment Agreement (the “Investment Agreement) with A.DT.C. S.r.l. (“A.T.C.”), a ~~Francesco~~private ~~Galimi~~Italian manufacturer of high-precision tactical rifles, Mspecial-forces weapon systems, and competition-grade sporting firearms.D. Pursuant to the Investment Agreement, Phthe Company will acquire an initial 19.D5% equity ownership in A.T.C. for €1.275 million, with the opportunity to acquire up to 51% equity ownership over multiple closings for a total of €5.1 million, subject to A.T.C. meeting certain turnover and ~~Pierluigi~~EBITDA ~~Paracchi~~performance milestones and maintaining the licenses required under Italian law to conduct its business activity. Additionally, ~~Chief~~the ~~Executive~~Investment ~~Officer~~Agreement provides for a put option in favor of the Company, ~~will~~pursuant ~~continue~~to which the Company is entitled to ~~serve~~sell onits ~~the~~entire ~~Board~~equity interest in A.T.C. back to A.T.C.’s existing shareholders if (i) A.T.C.’s required licenses are revoked or suspended for at least two months or (ii) A.T.C. achieves less than 30% of ~~Directors;~~the applicable turnover and EBITDA milestones. The consideration for such sale will equal the Company’s total investment at the time the put option is exercised. The Investment Agreement contains representations and warranties, covenants and closing conditions, customary for a transaction of this nature.

●The foregoing todescription ~~grant~~of the ~~newly~~Investment ~~appointed~~Agreement ~~directors~~does annot ~~aggregate~~purport ~~annual~~to ~~gross~~be ~~compensation~~complete ofand ~~€60,000~~is ~~per~~qualified ~~year,~~in toits beentirety ~~distributed~~by ~~among~~reference ~~them~~to by the full ~~Board~~text of ~~Directors.~~the ~~Therefore~~Investment Agreement, ~~the~~a ~~overall~~copy ~~remuneration~~ of ~~the~~which ~~entire~~is ~~Board~~filed isas Exhibit 10.1 to bethis ~~considered~~Current ~~redetermined~~Report inon ~~the~~Form ~~amount~~6-K of(this ~~€165,000~~“Report”) and is incorporated by reference herein.

~~The~~Shareholders’ new director, Miguel Maria Mutti, is a senior executive with over 25 years of international experience in the pharmaceutical and investment banking sectors. He has a proven track record in corporate and business development, M&A, licensing, and general management, having led major growth, restructuring, and integration projects across Europe, Latin America, and Asia. Currently, he serves as Managing Partner at Sinergetica Healthcare, a strategic consulting and investment firm focused on pharma, biotech, and medtech. Before that, he held senior leadership roles at Lupin Limited, Grünenthal GmbH, Chemo Group, and Citigroup. Mr. Mutti combines strategic vision, financial expertise, and hands-on operational leadership, supported by an MBA from ISTUD and executive training at INSEAD. He is fluent in Italian, Spanish, and English.Agreement

~~The~~On ~~new~~January ~~director~~25, ~~Giacomoantonio Paracchi~~2026, isthe aCompany ~~business~~entered ~~lawyer~~into ~~with~~a ~~extensive~~Shareholders’ ~~experience~~Agreement as(the ~~General~~“SHA”) ~~Counsel~~with ~~and~~Pierluigi ~~Head~~Paracchi, ~~of Legal & Corporate~~the ~~Affairs~~Company’s ~~within~~Chief ~~structured~~Executive ~~multinational groups. Since September 2023~~Officer, heChairman ~~has~~of ~~been~~the ~~serving~~Board ~~as General Counsel~~ of Directors (the ~~Geodis~~“Board”) ~~Group,~~ and ~~since~~ ~~May 2025~~co-founder, heand ~~has~~Fondazione Praexidia ~~also~~(the ~~joined~~“Foundation”). ~~LEXIA~~Prior asto ~~a Partner in~~ the ~~Corporate~~SHA, ~~/ M&A / Capital Markets Department~~Mr. ~~Previously,~~Paracchi hedonated ~~held senior legal and corporate positions at Comifar Group~~3,000 ~~Valtellina~~of ~~Group,~~his ~~and~~American ~~Techint~~Depositary ~~Group,~~Shares ~~overseeing~~in ~~legal,~~the ~~corporate~~Company to ~~affairs,~~the ~~and compliance functions~~Foundation. ~~His~~The ~~professional~~Foundation ~~background~~ is ~~complemented by~~ an ~~excellent~~Italian ~~command~~private offoundation ~~the~~that ~~English~~brings ~~language~~together ~~and~~senior afigures ~~strong~~from ~~focus~~Italian ongovernment ~~business-oriented~~institutions, ~~legal strategy. Mr. Paracchi is~~ the ~~brother~~defense ~~of Pierluigi Paracchi~~industry, and the ~~Company’s~~armed ~~Chief Executive Officer, Chairman and co-founder~~forces.

The ~~effectiveness~~SHA of(having ~~the~~a byfive-~~laws~~year ~~amendment~~term, toautomatically ~~Article~~renewable 4,for ~~extending~~additional ~~the~~five-year ~~Company~~periods unless terminated by either party with at least one month’s ~~corporate~~prior ~~purpose~~written tonotice) ~~include~~provides ~~all~~for ~~sectors~~mutual ~~covered~~commitments byand consultation procedures between the Foundation and Mr. Paracchi regarding transactions subject to the Italian Golden Power ~~legislation,~~regime (“Significant Transactions”). For Board meetings at which a Significant Transaction is ~~expressly~~on ~~conditioned~~the ~~upon~~agenda, Mr. Paracchi must inform the Foundation, which may then provide its non-~~exercise~~binding ofopinion to the ~~withdrawal~~Board. ~~right~~Mr. ~~(diritto~~Paracchi diwill ~~recesso) granted~~ensure such opinion is presented to ~~shareholders~~the ~~who~~Board, ~~did~~but ~~not~~the ~~vote~~Board inand ~~favor~~Mr. ofParacchi ~~the~~retain ~~resolution~~full ~~(as~~discretion ~~absent,~~in their ~~abstained,~~respective orresolutions ~~voted~~and ~~against)~~votes.

~~Should~~If ~~even~~ a ~~single~~Significant ~~withdrawal~~Transaction beis ~~validly~~subject ~~exercised,~~to ~~the~~approval ~~above~~at ~~by-laws~~a ~~amendment~~shareholders’ ~~will~~meeting, ~~not~~Mr. ~~take~~Paracchi ~~effect;~~and ~~therefore,~~the inFoundation ~~this~~will ~~case,~~consult with the ~~exercise of~~aim, ~~the~~but ~~right~~not ofthe ~~withdrawal~~obligation, ~~will~~to ~~not~~determine ~~entitle~~common ~~the~~voting ~~withdrawing~~indications. ~~shareholder~~If tothey ~~the~~do ~~liquidation~~not ofreach ~~the~~a ~~relevant~~common ~~shares~~position, ~~and~~each ~~will~~party ~~only~~may ~~determine~~vote ~~the~~independently. ~~ineffectiveness~~The ofSHA ~~the~~does ~~resolution~~not ofgrant the ~~Shareholders’~~Foundation ~~Meeting~~any management power over the Company.

The ~~right~~SHA ofincludes ~~withdrawal~~a ~~must~~lock-up beon ~~exercised~~the ~~pursuant~~shares toheld ~~Article~~by ~~2347-bis~~Mr. ofParacchi and the ~~Italian~~Foundation. ~~Civil~~The ~~Code,~~lock-up byis ~~sending~~subject ato ~~registered~~certain ~~letter~~customary toexceptions, ~~the~~including ~~Company~~for ~~within~~transfers ~~fifteen~~to ~~days~~an ~~from~~affiliate (provided the ~~registration~~affiliate ofadheres to the ~~shareholders’~~SHA), ~~resolution~~transfers inrequired ~~the~~by ~~Companies’ Register~~law, ~~i.e. by~~and ~~about~~in ~~November~~connection ~~15,~~with a ~~2025.~~public ~~The~~tender ~~letter~~offer ~~must~~for ~~include~~a majority of the ~~shareholder~~Company’s ~~personal~~share ~~details,~~capital. ~~the~~Mr. ~~address~~Paracchi ~~for~~is ~~communications~~also ~~related~~ permitted to ~~the~~transfer ~~procedure,~~any ~~and~~shares he holds in excess of the number ofrequired ~~shares~~to ~~for~~maintain ~~which~~majority ~~the~~voting ~~right~~power ofin ~~withdrawal~~the isCompany’s ~~exercised~~shareholders’ meetings.

~~For~~The ~~any~~foregoing ~~further~~description ~~information,~~of ~~shareholders~~the ~~who~~SHA ~~intend~~does not purport to ~~exercise~~be ~~the~~complete ~~right~~and ofis ~~withdrawal~~qualified ~~are~~in ~~kindly~~its ~~invited~~entirety toby ~~contact~~reference to the ~~Company~~full attext of the ~~certified~~SHA, ~~e-mail~~a ~~address~~copy ~~amministrazione@genenta~~of which is filed as Exhibit 10.~~com~~2 to this Report and is incorporated by reference herein.

~~The~~Initiation ~~above description~~ of ~~the~~Legal by-laws amendment is qualified in its entirety by reference to the by-laws, a copy of which is filed as Exhibit 3.1 hereto and is incorporated herein by reference (please note that such copy of the by-laws do not provide yet the current amount of the Company’s share capital following the issuance of n. 4,285,715 new shares in the context of the capital increase and the related offering pursuant to the prospectus supplement filed on October 28, 2025; such updated by-laws will be filed with the Companies’ Register, in accordance with Article 2444 of the Italian Civil Code, within 30 days from the execution of the capital increase).Proceedings

Exhibits
Exhibit No.		Description
3.1		Amended By-laws of Genenta Science S.p.A.

On January 27, 2026, the Company commenced legal proceedings before the Court of Milan against Fondazione Enea Tech Biomedical (“ETB”), with which the Company previously entered into a EUR 20 million convertible bond loan agreement in March 2025 (the “Agreement”). Under the Agreement, the Company has received, to date, only EUR 7.5 million. The lawsuit seeks, inter alia, to have the Agreement declared null and void and to recover damages. The basis of the Company’s claim is that ETB, which entered into a memorandum of understanding in 2022 and later (through two different term sheets) postponed signing of the Agreement until March 2025 – at which time it also changed the amount, number of installments, and other loan terms – acted in bad faith and rendered the Agreement void for lack of cause. There can be no assurance as to the outcome of this or any other future proceedings or litigation.

~~SIGNATURES~~Forward-Looking Statements

~~Pursuant~~This Report contains forward-looking statements that involve risks and uncertainties, such as statements related to the ~~requirements~~Company’s anticipated acquisition of ~~the~~equity ~~Securities~~ownership ~~Exchange~~in ~~Act~~A.T.C. ofThe ~~1934~~risks and uncertainties involved include A.T.C.’s ability to satisfy the applicable performance-based criteria, asmarket ~~amended~~conditions, and other risks detailed from time to time in the ~~registrant~~Company’s ~~has~~periodic reports ~~duly~~and ~~caused~~other ~~this~~filings ~~report~~with the SEC. You are cautioned not to beplace ~~signed~~undue reliance on ~~its~~forward-looking statements, which are based ~~behalf~~on bythe Company’s current expectations and assumptions and speak only as of the ~~undersigned~~date ~~hereunto~~of ~~duly~~this ~~authorized~~Report. The Company does not intend to revise or update any forward-looking statement in this Report as a result of new information, future events or otherwise, except as required by law.

	GENENTA SCIENCE S.P.A.
Dated: November 3, 2025	By:	/s/ Richard B. Slansky
	Name:	Richard B. Slansky
	Title:	Chief Financial Officer

SUBMITTED HEREWITH

Attached to this Report for the month of January 2026, and incorporated by reference herein, is:

Exhibit No.		Description

10.1		Investment Agreement dated January 24, 2026, between the Company and A.T.C. S.r.l.

10.2		Shareholders’ Agreement dated January 25, 2026 between the Company, Pierluigi Paracchi, and Fondazione Praexidia.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GENENTA SCIENCE S.P.A.

Date: January 27, 2026	By:	/s/ Pierluigi Paracchi
		Pierluigi Paracchi, Chief Executive Officer

Filing Compare · Genenta Science S.p.A.